Panbela Therapeutics Inc. (PBLA)
| Bid | n/a |
| Market Cap | 1.8M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -27.9M |
| EPS (ttm) | -34.51 |
| PE Ratio (ttm) | -0.01 |
| Forward PE | -0.07 |
| Analyst | Hold |
| Ask | n/a |
| Volume | 23,001 |
| Avg. Volume (20D) | 20,888 |
| Open | 0.40 |
| Previous Close | 0.43 |
| Day's Range | 0.36 - 0.40 |
| 52-Week Range | 0.30 - 1.32 |
| Beta | 0.90 |
About PBLA
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, ...
Analyst Forecast
According to 2 analyst ratings, the average rating for PBLA stock is "Hold." The 12-month stock price forecast is $25, which is an increase of 6656.76% from the latest price.
3 months ago · seekingalpha.com
Panbela Therapeutics, Inc. (PBLA) Q3 2024 Earnings Call TranscriptPanbela Therapeutics, Inc. (OTCQB:PBLA) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Jennifer Simpson - CEO Sue Horvath - CFO Conference Call Participants Jonatha...